Press

Numinus Wellness Inc. Executives to Present on Panel at Upcoming South by Southwest Conference

Mar 8 • 3 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will be featured on a panel at the upcoming South by Southwest Conference taking place in Austin, Texas, on March 10 – 19, 2023. The panel, titled Music as Medicine: Music as a Tool for Healing, will be held on March 10,…

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

Mar 8 • 6 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces further positive results from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”). The trial investigated the efficacy and…

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Mar 8 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that management will participate in the Oppenheimer Annual Healthcare Conference as part of the biotechnology virtual corporate presentation on Tuesday, March 14, 2023 at 4:00 PM Eastern Time…

Safe Supply and Origin Therapeutics Announces Engagement of Research Capital and Upsizing of Brokered Financing To $4 Million

Mar 7 • 4 min read

Safe Supply Streaming Co. Ltd. and Origin Therapeutics Holdings Inc. (CSE: ORIG | FSE: U8B) are pleased to announce the upsizing of their previously disclosed private placement offering of subscription receipts (the “Subscription Receipts”) from $3 million to $4 million in aggregate gross proceeds. The Offering is being led by Research Capital Corporation as the…

Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Mar 6 • 3 min read

Incannex Healthcare Limited (Nasdaq: IXHL | ASX: IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Catalent (‘Catalent’) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435